LUCAR-G39D / Legend Biotech - LARVOL DELTA

Advance Cell Therapy Innovation (The Manila Times) - "Dosed first patient with in vivo platform technology, a dual CD20/CD19-targeted cell therapy, within six months of candidate selection; First-in-human data expected starting in the second half of 2026; Targeting multiple investigational new drug (IND) filings for oncology and autoimmune indications starting in 2H 2026."

First-in-human • IND • P1 data • Trial status • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Immunology • Large B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A phase 1 study of lucar-G39D: A novel anti-CD20/CD19 dual-CAR allogeneic gamma delta T cells in adults with relapsed / refractory B-cell non-Hodgkin lymphoma (NHL) (ASH 2025) - P1 | "All patients received moderate conditioning therapy with fludarabine (30mg/m2) andcyclophosphamide (500mg/m2) per day for 3-4 days followed by a single infusion of LUCAR-G39D at doselevel 1 (DL1):30×106, DL2:100×106, DL3:200×106, or DL4:400×106 CAR-T cells. LUCAR-G39D γδ CAR-T cells showed a manageable safety profile and good expansion inpatients with NHL. Preliminary efficacy showed encouraging response rate and sustained durability inpatients; this therapeutic strategy warrants further investigation."

Clinical • IO biomarker • P1 data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Pneumonia • Primary Mediastinal Large B-Cell Lymphoma • Respiratory Diseases • CD19

Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) - "Two oral and seven poster presentations further support the CARVYKTI research in multiple myeloma....In addition to the CARVYKTI data, the Company will also deliver an oral presentation on Lucar-G39D, its investigational and novel anti-CD20/CD19 dual-CAR allogeneic gamma delta T cell therapy, being evaluated in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL)."

Clinical data • B Cell Non-Hodgkin Lymphoma • Multiple Myeloma

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=33 | Recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=33 | Not yet recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology